Considering that the latter efficiently treats G‐CSF‐producing MM, [2] a daratumumab‐based regimen, as well as a cytotoxic agent regimen, may be good choices for G‐CSF‐producing MM with BMF. The gene discussed is CSF3; the disease is Miyoshi myopathy.